Case Study: GLP-1 Cost Effectiveness and Coverage for Employer-Sponsored Health Plans
GLP-1 receptor agonists, or GLP-1 RAs, are changing the game for people living with Type 2 diabetes and obesity. These powerful medications, such as Ozempic, Trulicity, and Wegovy, not only help manage blood sugar levels but have also shown significant benefits in weight loss. However, due to their high cost and increasing demand, health plans and employers are facing challenges in providing coverage for these drugs.
Employer-sponsored health plans can expect a significant increase in claims expenses for GLP-1 drugs. For example, a company with 1,000 employees could spend around $600,000 in 2024. While GLP-1 drugs offer undeniable health benefits, including reduced rates of heart-related issues and a decrease in BMI, the financial strain on payers and the necessity of patient adherence to treatment plans underscore the complexity of incorporating these drugs into healthcare coverage.
Download our recent case study to gain a deeper understanding of GLP-1 receptor agonists and their impact on health plan coverage. It provides a detailed analysis of cost and utilization trends and the steps employers can take to manage this growing expense while supporting their employees' health.
Ready to Learn More?
What is the true future risk? Download our case study to better understand GLP-1 receptor agonists and their impact on health plan coverage.
Related articles
It is standard practice that stock purchases include language requiring the purchase of D&O tail insurance covering the Seller’s directors and officers. Seller’s counsel may push for the addition of...
At the end of each year, AIG releases a Representations and Warranties claims report. Being one of the earliest insurers in the space, AIG has robust and comprehensive data about claims in the...
The process of procuring Representations and Warranties Insurance (“RWI”) has been significantly impacted by all the same factors that weighed on the M&A market in 2023. For potential acquirers...